+44 20 8123 2220
info@marketpublishers.com

Scleroderma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

https://marketpublishers.com/r/S1B033D767C8EN.html
Date: May 2024
Pages: 136
Price: US$ 6,499.00 (Single User License)
ID: S1B033D767C8EN

Abstracts

The 7 major scleroderma markets are expected to exhibit a CAGR of 4.38% during 2024-2034.

The scleroderma market has been comprehensively analyzed in IMARC's new report titled "Scleroderma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Scleroderma, also referred to as systemic sclerosis, is a rare autoimmune disease that affects the connective tissues of the body. This condition causes the hardening and tightening of the skin and internal organs, which can lead to serious problems in the blood vessels and digestive tract. The symptoms of the ailment can vary widely depending on the type and severity of the disease, but can include joint pain and stiffness, shortness of breath, and difficulty swallowing. Individuals suffering from scleroderma may also experience small red spots, itchiness, heartburn, diarrhea, fecal incontinence, bloating, decreased exercise tolerance, dizziness, etc. The diagnosis of this condition relies on the identification of a patient's symptoms, medical history, and physical exam. The healthcare professional may also perform blood tests to validate elevated levels of specific antibodies produced by the immune system. Numerous imaging and organ-function tests are utilized among patients to help determine the extent and areas affected.

The rising cases of autoimmune disorders, which cause inflammation and excess collagen production in the affected cells, thereby leading to damage as well as scarring, are primarily driving the scleroderma market. Besides this, the increasing prevalence of various associated risk factors, such as gene variations, repeated exposure to certain harmful substances or chemicals, viral infections, etc., is also augmenting the market growth. Furthermore, the widespread adoption of calcium channel blockers and proton

+44 20 8123 2220
info@marketpublishers.com

pump inhibitors, which respectively relax blood vessels and reduce acid release in the stomach, thereby providing symptom relief, is creating a positive outlook for the market. In addition to this, the escalating utilization of physical and occupational therapy for stabilizing strength and mobility, as well as maintaining independence with daily tasks among patients, is acting as another significant growth-inducing factor. Moreover, the emerging popularity of combination treatment, including light therapy and pharmacological medications, such as methotrexate, mycophenolate mofetil, cyclophosphamide, etc., since they target to suppress the immune system, minimize skin thickening, and prevent damage to the internal organs, is expected to drive the scleroderma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the scleroderma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for scleroderma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the scleroderma market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain

+44 20 8123 2220
info@marketpublishers.com

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the scleroderma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the scleroderma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current scleroderma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the scleroderma market performed so far and how will it perform in the coming years?

+44 20 8123 2220
info@marketpublishers.com

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the scleroderma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the scleroderma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of scleroderma across the seven major markets?
What is the number of prevalent cases (2018-2034) of scleroderma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of scleroderma by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of scleroderma by type across the seven major markets?
How many patients are diagnosed (2018-2034) with scleroderma across the seven major markets?
What is the size of the scleroderma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of scleroderma?
What will be the growth rate of patients across the seven major markets?

Scleroderma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for scleroderma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the scleroderma market?

+44 20 8123 2220
info@marketpublishers.com

What are the key regulatory events related to the scleroderma market?
What is the structure of clinical trial landscape by status related to the scleroderma market?
What is the structure of clinical trial landscape by phase related to the scleroderma market?
What is the structure of clinical trial landscape by route of administration related to the scleroderma market?

+44 20 8123 2220
info@marketpublishers.com

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 SCLERODERMA - INTRODUCTION

4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 SCLERODERMA - DISEASE OVERVIEW

5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 PATIENT JOURNEY

7 SCLERODERMA - EPIDEMIOLOGY AND PATIENT POPULATION

7.1 Epidemiology - Key Insights

+44 20 8123 2220
info@marketpublishers.com

7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)

+44 20 8123 2220
info@marketpublishers.com

7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)

8 SCLERODERMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 SCLERODERMA - UNMET NEEDS

10 SCLERODERMA - KEY ENDPOINTS OF TREATMENT

11 SCLERODERMA - MARKETED PRODUCTS

11.1 List of Scleroderma Marketed Drugs Across the Top 7 Markets

+44 20 8123 2220
info@marketpublishers.com

11.1.1 Actemra (Tocilizumab) - Chugai Pharmaceutical/Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Ofev (Nintedanib) - Boehringer Ingelheim
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Azanin (Azathioprine oral dispersible) - Mitsubishi Tanabe
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 SCLERODERMA - PIPELINE DRUGS

12.1 List of Scleroderma Pipeline Drugs Across the Top 7 Markets
12.1.1 GS248 - Gesynta Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Guselkumab - Janssen Biotech
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 FCR001 - Talaris Therapeutics Inc.
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action

+44 20 8123 2220
info@marketpublishers.com

12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Tofacitinib - Pfizer
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 BI685509 - Boehringer Ingelheim
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. SCLERODERMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. SCLERODERMA – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 SCLERODERMA - MARKET SCENARIO

15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Scleroderma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Scleroderma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States

+44 20 8123 2220
info@marketpublishers.com

15.3.1 Scleroderma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Scleroderma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Scleroderma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Scleroderma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Scleroderma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Scleroderma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Scleroderma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Scleroderma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Scleroderma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Scleroderma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Scleroderma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Scleroderma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Scleroderma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Scleroderma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Scleroderma - Access and Reimbursement Overview

+44 20 8123 2220
info@marketpublishers.com

15.8 Market Scenario - Spain
15.8.1 Scleroderma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Scleroderma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Scleroderma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Scleroderma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Scleroderma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Scleroderma - Access and Reimbursement Overview

16 SCLERODERMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 SCLERODERMA MARKET - SWOT ANALYSIS

17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 SCLERODERMA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Scleroderma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: https://marketpublishers.com/r/S1B033D767C8EN.html

Price: US$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/S1B033D767C8EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

+44 20 8123 2220
info@marketpublishers.com